Meeting
2023 ASCO Quality Care Symposium
Time toxicity in early-phase clinical trials.
Authors
Sienna Durbin
Massachusetts General Hospital, Boston, MA
Sienna Durbin, Debra Lundquist, Andrea Pelletier, Rachel Jimenez, Laura A Petrillo, Janice Kim, Kaitlyn Lynch, Megan Healy, Andrew Johnson, Nicholas Ollila, Benjamin Malowitz, Allison Kehlmann, Nicholas Chevalier, Victoria Turbini, Viola Bame, Hope Heldreth, Casandra McIntyre, Dejan Juric, Ryan David Nipp
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care
Sub Track
Access to Clinical Trials
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 104)
DOI
10.1200/OP.2023.19.11_suppl.104
Abstract #
104
Poster Bd #
B11
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial.
First Author: John Robert Mackey
Poster
2013 ASCO Annual Meeting
Safety and efficacy of the HER2-derived GP2 peptide vaccine in combination with trastuzumab for breast cancer patients in the adjuvant setting.
First Author: Ritesh Patil
Poster
2013 Genitourinary Cancers Symposium
Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials.
First Author: Orazio Caffo
Poster
2024 ASCO Annual Meeting
Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer.
First Author: Sherry Shen